Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$62.01
$0.74(1.19%)
At close: 4:00 PM EST
$62.01
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)896.85K
Market Cap
$2.37B
Enterprise Value$2.20B
Total Cash (Recent Filing)$791.15M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
May 07, 2026EPS Estimate
-1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding38,160,065
10 Day Avg. Volume618,592
30 Day Avg. Volume896,845
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.52K
Enterprise Value/Ebitda-10.64
Forecast
1Y Price Target
$99.60Price Target Upside60.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.86
Revenue Forecast (FY)$6.08M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA sizable cash position expected to fund operations through multiple upcoming catalysts reduces near-term financing risk and supports continued development and regulatory engagement.
Pipeline DiversificationInitiation of a Phase 2 study for DISC-0974 in inflammatory bowel disease-associated anemia and encouraging early hepcidin induction for DISC-3405 could broaden the company's clinical footprint and materially de-risk additional assets if future data are positive.
Pivotal Clinical ReadoutAn upcoming APOLLO trial readout could show reductions in the disease biomarker and improved sunlight tolerance, creating a clear efficacy case that may reopen the path for traditional approval of the lead drug.
Bears Say
Biomarker Validity RiskFDA concern that reductions in the PPIX biomarker may not reliably predict improved sunlight tolerance raises the possibility that additional clinical evidence beyond biomarker changes will be required for approval.
Regulatory SetbackA complete response letter from the FDA created uncertainty around the approval pathway for the lead drug and prompted a strategic restructuring, which may pressure the stock until regulatory clarity is achieved.
Restructuring And Workforce ReductionA reduction of about one-fifth of the workforce, concentrated in commercial and support roles, will generate one-time severance charges and could slow commercial readiness and execution even if regulatory issues are resolved.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $30.82 and its highest was $99.50 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $2.37B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Feb 26, 2026. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.71 by $0.07.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.65.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 38,160,065 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.71. Following the earnings report the stock price went up 1.525%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.60 (60.62% Upside)
$99.60 (60.62% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 532.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.13%
12-Months-Change
Fundamentals
Return on Equity
-32.80%
Trailing 12-Months
Asset Growth
62.42%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$99.60
▲(60.62% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.88% Insiders
28.11% Mutual Funds
44.19% Other Institutional Investors
7.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---